First preservative-free prostaglandin treatment approved

June 1, 2008

Taflotan (tafluprost; Santen Oy), a benzalkonium chloride (BAK)-free prostaglandin analogue for the treatment of glaucoma, has received marketing authorization in Denmark and Germany, making it the first preservative-free prostaglandin eye drop to be approved.

Taflotan (tafluprost; Santen Oy), a benzalkonium chloride (BAK)-free prostaglandin analogue for the treatment of glaucoma, has received marketing authorization in Denmark and Germany, making it the first preservative-free prostaglandin eye drop to be approved.

Taflotan has been shown to be reduce intraocular pressure by 27–31% in open angle glaucoma and ocular hypertension, with hyperaemia as the most commonly reported adverse event (13%).

Taflotan is indicated as monotherapy for patients who are intolerant to or contraindicated for first-line treatment, and as an adjunct to beta-blockers. It is especially recommended for patients who might suffer BAK-related side effects, such as those with dry or sensitive eyes.